EUVIMEDEUVIMED entdecken
Crossref

PI-RADS–stratified MRI-based PSA Density for Predicting Adverse Pathology after Robotic-assisted Laparoscopic Radical Prostatectomy

Hangcheng Fu, Braden Millan, Patrick Michael, Ruben Blachman-Braun, Jaskirat Saini, Cody Ewing, Mitchell Hwang, Maria J Merino, Michael Ahdoot, Sandeep Gurram, Baris Turkbey, Peter A Pinto

European Urology Focus · 2026-10 · 12 (5) · 956-964

DOI: 10.1016/j.euf.2026.04.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Hangcheng Fu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Prostate-Specific Antigen, Robotic Surgical Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Institutes of Health, U.S. Department of Health and Human Services, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the modern magnetic resonance imaging (MRI) era, prostate-specific antigen (PSA) density (PSAD) derived from multiparametric MRI (mpMRI) has become an accessible biomarker for risk stratification in localized prostate cancer. Although widely used, the optimal PSAD threshold for predicting adverse pathology and long-term oncologic outcomes after radical prostatectomy remains uncertain. OBJECTIVE: To determine the prognostic utility and optimal cutoff of MRI-based PSAD in predicting adverse pathology and oncologic outcomes among men undergoing robotic-assisted laparoscopic radical prostatectomy (RALP). DESIGN, SETTING, AND PARTICIPANTS: This study analyzed a prospectively maintained MRI-era cohort of 788 consecutive patients who underwent RALP between 2006 and 2023. All patients had preoperative mpMRI with volumetric assessment, pathology data, and long-term follow-up for biochemical and metastatic progression. The primary endpoint was adverse pathology, defined as ≥pT3 disease, Grade Group ≥4, seminal vesicle invasion (SVI), lymph-node positivity, or positive surgical margin (PSM). Secondary outcomes included biochemical recurrence-free survival (BRFS). RESULTS: Median age was 62.5 yr, median was PSA 6.7 ng/ml, median prostate volume was 40.0 ml, and median MRI-based PSAD was 0.16 ng/ml/cm3. Adverse pathology occurred in 43% of patients, with 15.7% harboring PSMs, 7.4% SVI, and 4.7% nodal involvement. On multivariable analysis, MRI-based PSAD independently predicted adverse pathology (odds ratio [OR] 15.633, p < 0.001), SVI (OR 2.614, p = 0.040), PSM (OR 3.650, p = 0.028), and PSA persistence (OR 4.463, p = 0.004). Decision-curve analysis demonstrated that PSAD ≥ 0.10 ng/ml/cm3 provided the greatest overall net benefit in Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 for predicting adverse pathology, while PSAD ≥0.15 ng/ml/cm3 achieved better specificity and performed best in men with PI-RADS ≤2. Kaplan-Meier analyses showed significantly worse BRFS for PSAD ≥0.15 ng/ml/cm3 versus

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyProstate-Specific AntigenRobotic Surgical ProceduresLaparoscopyMultiparametric Magnetic Resonance ImagingHumansMaleMiddle AgedAgedPrognosisPredictive Value of TestsMagnetic Resonance ImagingProspective Studies

Stichwörter der Autor:innen

Adverse pathologyBiochemical recurrencePI-RADSPSA densityProstate cancer

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Department of Urology, Walter Reed Army Medical Center, Bethesda, MD, USA.
  • Department of Urology, Cedars Sinai Medical Center, LA, USA.
  • Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: pintop@mail.nih.gov.

Förderung

  • National Institutes of Health
  • U.S. Department of Health and Human Services
  • National Cancer Institute

Zitieren

APA

Fu, H., Millan, B., Michael, P., Blachman-Braun, R., Saini, J., Ewing, C., Hwang, M., Merino, M. J., Ahdoot, M., Gurram, S., Turkbey, B., & Pinto, P. A. (2026). PI-RADS–stratified MRI-based PSA Density for Predicting Adverse Pathology after Robotic-assisted Laparoscopic Radical Prostatectomy. European Urology Focus, 12(5), 956-964. https://doi.org/10.1016/j.euf.2026.04.017

Vancouver

Fu H, Millan B, Michael P, Blachman-Braun R, Saini J, Ewing C, et al. PI-RADS–stratified MRI-based PSA Density for Predicting Adverse Pathology after Robotic-assisted Laparoscopic Radical Prostatectomy. European Urology Focus. 2026;12(5):956-964. doi:10.1016/j.euf.2026.04.017

BibTeX
@article{Fu2026,
  author = {Fu, Hangcheng and Millan, Braden and Michael, Patrick and Blachman-Braun, Ruben and Saini, Jaskirat and Ewing, Cody and Hwang, Mitchell and Merino, Maria J and Ahdoot, Michael and Gurram, Sandeep and Turkbey, Baris and Pinto, Peter A},
  title = {PI-RADS–stratified MRI-based PSA Density for Predicting Adverse Pathology after Robotic-assisted Laparoscopic Radical Prostatectomy},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {956--964},
  doi = {10.1016/j.euf.2026.04.017}
}
Kostenlos starten →